Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre StudyTiago Torres, Paolo Gisondi, Ricardo Romiti et al.|American Journal of Clinical Dermatology|2024Cited by 58
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Antonio Costanzo, Alessandra Narcisi et al.|Frontiers in Medicine|2023Cited by 55
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)Diego Orsini, Antonio Costanzo, Piergiorgio Malagoli et al.|Dermatology Practical & Conceptual|2024Cited by 34
Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational StudyFrancesco Bellinato, Giampiero Girolomoni, Paolo Gisondi et al.|Vaccines|2023Cited by 22
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba et al.|Journal of Dermatological Treatment|2024Cited by 21